Cargando…

Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis()

A retrospective cohort study, were evaluated: polymyxin B plus aminoglycosides or polymyxin B plus other antibiotics. Any degree of acute kidney injury occurred in 26 (86.6%) patients. The median time to acute kidney injury was 6.0 (95% CI 3–14) days in the polymyxin-aminoglycoside containing regime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abboud, Cely Saad, Rao, Gauri G., Souza, Ercilia E., Zavascki, Alexandre P., Kiffer, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425646/ https://www.ncbi.nlm.nih.gov/pubmed/29182906 http://dx.doi.org/10.1016/j.bjid.2017.10.006

Ejemplares similares

487 Infections Caused by Enterobacteriaceae Species following Cardiac Surgery: Impact of Polymyxin Resistance on Treatment Outcomes
por: Abboud, Cely Saad, et al.
Publicado: (2014)

Successful use of gentamycin as an antibiotic prophylaxis regimen to reduce the rate of healthcare-associated infections after renal transplantation
por: Abboud, Cely S., et al.
Publicado: (2013)

2246. Improved Outcomes for Cancer Patients Treated With Ceftazidime–Avibactam vs. Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia
por: Borjan, Jovan, et al.
Publicado: (2019)

Polymyxin B Etest Fails to Distinguish Carbapenem-resistant Enterobacteriaceae with Elevated Polymyxin B MICs
por: Kulengowski, Brandon, et al.
Publicado: (2017)

Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae
por: Diep, John K., et al.
Publicado: (2018)

Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates
por: Barin, Juliana, et al.
Publicado: (2013)

Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii
por: Chang, Kang, et al.
Publicado: (2022)

Overview of polymyxin resistance in Enterobacteriaceae
por: da Silva, Kesia Esther, et al.
Publicado: (2022)

2262. Ceftazidime–Avibactam vs. Polymyxin B in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
por: John, Jamie, et al.
Publicado: (2019)

Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis
por: Ni, Wentao, et al.
Publicado: (2015)

A Cohort Study of the Impact of Carbapenem-Resistant Enterobacteriaceae Infections on Mortality of Patients Presenting with Sepsis
por: Sabino, Sabrina, et al.
Publicado: (2019)

NDM-producing Enterobacterales prevalence associated to Covid-19 in a tertiary hospital
por: Monteiro, Jussimara, et al.
Publicado: (2022)

Use of Carbapenems, Polymyxins, and Tigecycline in United States Children’s Hospitals, 2010–2014
por: Chiotos, Kathleen, et al.
Publicado: (2017)

Polymyxin B Resistance in Carbapenem-Resistant Klebsiella pneumoniae, São Paulo, Brazil
por: Bartolleti, Flávia, et al.
Publicado: (2016)

Rapid Detection of Polymyxin Resistance in Enterobacteriaceae
por: Nordmann, Patrice, et al.
Publicado: (2016)

In vitro activity of non-bactericidal concentrations of polymyxin B in combination with other antimicrobials against OXA-23-producing carbapenem-resistant Acinetobacter baumannii
por: Netto, Bárbara, et al.
Publicado: (2013)

Emerging Transcriptional and Genomic Mechanisms Mediating Carbapenem and Polymyxin Resistance in Enterobacteriaceae: a Systematic Review of Current Reports
por: Mmatli, Masego, et al.
Publicado: (2020)

Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection
por: Liang, Qiqiang, et al.
Publicado: (2019)

The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae
por: Luterbach, Courtney L, et al.
Publicado: (2018)

Increased 30-Day Mortality Associated With Carbapenem-Resistant Enterobacteriaceae in Children
por: Chiotos, Kathleen, et al.
Publicado: (2018)

The Predominance of Klebsiella aerogenes among Carbapenem-Resistant Enterobacteriaceae Infections in Japan
por: Kamio, Kosuke, et al.
Publicado: (2022)

Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis
por: Prayag¹, Parikshit S, et al.
Publicado: (2023)

Efficacy and safety of ceftazidime–avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis
por: Yang, Ping, et al.
Publicado: (2023)

Profile of the Gut Microbiome Containing Carbapenem-Resistant Enterobacteriaceae in ICU Patients
por: Sindi, Anees A., et al.
Publicado: (2022)

Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy
por: Eilertson, Brandon, et al.
Publicado: (2017)

Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan
por: Wang, Jann-Tay, et al.
Publicado: (2015)

Resistance Pattern of Carbapenem on Enterobacteriaceae
por: Pokharel, Khilasa, et al.
Publicado: (2018)

Antimicrobial resistance in Enterobacteriaceae in Brazil: focus on β-lactams and polymyxins
por: Sampaio, Jorge Luiz Mello, et al.
Publicado: (2016)

Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity
por: Nation, Roger L., et al.
Publicado: (2019)

Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
por: Kanchanasurakit, Sukrit, et al.
Publicado: (2020)

Evaluation of phenotypic tests to detect carbapenem-resistant Enterobacteriaceae in colonized patients hospitalized in intensive care units
por: Perez, Leandro Reus Rodrigues, et al.
Publicado: (2015)

Use of polymyxins for carbapenem-resistant infections in children and adolescents
por: Barco-Cabrera, Carolina, et al.
Publicado: (2022)

1266. Melatonin for Renal Protection of Patients Treated with Polymyxin B: A Double Blind Randomized Clinical Trial
por: Rigatto, Maria Helena, et al.
Publicado: (2021)

Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study
por: Tang, Tiantian, et al.
Publicado: (2023)

2416. Risk Factors and Outcomes of Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae Compared With Carbapenem Susceptible Enterobacteriaceae
por: Mahmood, Syed Faisal
Publicado: (2018)

Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae: A Single-Center, Observational Study
por: Cancelli, F., et al.
Publicado: (2018)

Using Patient Risk Factors to Identify Whether Carbapenem-Resistant Enterobacteriaceae Infections Are Caused by Carbapenemase-Producing Organisms
por: Simner, Patricia J, et al.
Publicado: (2018)

Epidemiologic and Microbiologic Characteristics of Hospitalized Patients Co-colonized With Multiple Species of Carbapenem-Resistant Enterobacteriaceae in the United States
por: Adediran, Timileyin, et al.
Publicado: (2020)

Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients
por: Hanafin, Patrick O., et al.
Publicado: (2021)

Comparative genomic analyses of Polymyxin-resistant Enterobacteriaceae strains from China
por: He, Zhien, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_33bplelknov6ms3d6jqolp68t1